Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 10, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Why PTC Therapeutics, Inc. Shares Dipped
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 07, 12:37PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of PTC Therapeutics , a biopharmaceutical...
PTC Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update
PR Newswire - Thu Mar 06, 3:00PM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported its financial results for the fourth quarter and full-year ended December 31, 2013.
Financial Results Releases and Schedules, Clinical Study Results, Partnerships, and Senior-Level Appointments - Analyst Notes on Arena, Horizon Pharma, Enanta, Vanda, and PTC
PR Newswire - Wed Mar 05, 2:30PM CST
Editor Note: For more information about this release, please scroll to bottom.
PTC Therapeutics To Present At The Cowen & Company 34th Annual Health Care Conference
PR Newswire - Fri Feb 28, 7:00AM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that they will present a company overview at the Cowen & Company 34th Annual Health Care Conference on Wednesday, March 5th at 9:20 am ET at the Marriott Copley Plaza Hotel in Boston.
PTC Therapeutics announces inducement grant
M2 - Fri Feb 28, 3:38AM CST
US-based biopharmaceutical company PTC Therapeutics (NasdaqGS
PTC Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire - Thu Feb 27, 8:30PM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it granted a non-statutory stock option to purchase 150,000 shares of its common stock to Robert Spiegel, M.D., PTC's newly appointed Chief Medical Officer. The grant was made pursuant to the NASDAQ inducement grant exception as a component of Dr. Spiegel's employment compensation. The inducement grant was approved by PTC's Board of Directors on February 27, 2014 and is being made as an inducement material to Dr. Spiegel's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). PTC previously announced that Dr. Spiegel has been appointed Chief Medical Officer, effective January 23, 2014.
PTC Therapeutics to Host Fourth Quarter and Year End 2013 Financial Results Conference Call
PR Newswire - Thu Feb 27, 4:45PM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that will host a webcast conference call to discuss financial results for the fourth quarter and year end 2013 on Thursday, March 6, 2014 at 4:30 p.m. (ET) after the closing of the market.
PTC Therapeutics Expands International Commercial Team
PR Newswire Europe - Tue Feb 25, 7:02AM CST
PTC Therapeutics, Inc. today announced the appointment of Guido Schopen, M.D. to General Manager and Head of Medical Affairs for Europe. Dr. Schopen will be responsible for European commercial operations, reporting to Mark Rothera, Chief Commercial Officer of PTC.
PTC Therapeutics to Present at Upcoming Investor Conferences
PR Newswire - Thu Feb 20, 7:00AM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that they will participate in two upcoming investor conferences:
PTC Therapeutics Announces Closing of Registered Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
PR Newswire - Wed Feb 19, 12:00PM CST
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the closing of its previously announced registered public offering of 5,163,265 shares of its common stock, including 673,469 shares sold by PTC as a result of the full exercise by the underwriters of their option to purchase additional shares, at a price to the public of $24.50 per share. PTC expects its net proceeds from this offering to be approximately $118 million, after deducting the underwriting discounts and commissions and estimated expenses.
Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth
M2 - Fri Feb 14, 4:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/5ghfxl/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth" report to their offering. CFTR Modulators Instigate Cystic Fibrosis Market Surge The Cystic Fibrosis (CF) market will grow rapidly over the forecast period (2012-2019) at a Compound Annual Growth Rate (CAGR) of 30.6%. The sharp rise in market value is due to powerful new drugs entering the market, in particular the novel disease-modifying Cystic Fibrosis Transmembrane conductance Regulator (CFTR) modulators. Although very expensive, CFTR modulators are the first to act directly on the defective CFTR protein, which is the root cause of CF. As a result they represent the closest therapy to a cure currently available for CF patients. One CFTR modulator, Kalydeco (ivacaftor), is currently on the market, although it can only treat 5% of people with a specific mutation (O'Reilly and Elphick, 2013). Despite the low treatment population, it has already become one of the top-grossing drugs since its launch in 2012. A second CFTR modulator, lumacaftor, is expected to be launched in 2015. This drug is used in combination with Kalydeco and it is expected to be usable in over 80% of the CF population, which, combined with its large cost and uptake is expected to be the primary driver in the CF market surge. Increasing Life Expectancy Causes Rise in Prevalence The prevalence of CF will rise slowly over the forecast period by an estimated 10,000 cases. The primary cause of this is the increasing life expectancy of CF patients, which has rapidly grown over the past three decades as the understanding of the causes of CF has developed (Davies et al., 2007). CF incidence remains relatively constant as it is a hereditary disease; however the mortality rate is decreasing due to improvements in treatments and disease management. Therefore, the overall mortality rate is lower than the birth rate of CF patients and so the CF population is increasing. This will eventually reach equilibrium. The increasing prevalence is also a factor in terms of driving market growth, as many CF therapeutics must be taken indefinitely and on a regular basis. Key Drug Expiries Instigate Competition Several key drug expirations will occur in the forecast period. The drugs set to lose their patent protection are the mucolytic Pulmozyme (dornase alfa) and the antibiotics TOBI (tobramycin) and TOBI Podhaler (tobramycin). Cheap, generic versions of TOBI and TOBI Podhaler are expected to enter the market following their patent expiration, leading to an increase in the number of antibiotics on the market and an increase in competition. The number of Pulmozyme biosimilars and the impact on pricing is expected to be limited. The antibiotics segment of the market is predicted to become overcrowded in the forecast period, following the launch of several products with similar safety and efficacy profiles and the introduction of generic TOBI and TOBI Podhaler. Rather than one product dominating the antibiotics segment as is currently the case with TOBI, it is likely that each new product will acquire a smaller but more equal market share. Key Topics Covered 1 Table of Contents 2 Introduction 2.1 Disease Introduction 2.2 Symptoms 2.3 Etiology 2.4 Pathophysiology 2.5 Diagnosis 2.6 Prognosis 2.7 Assessment of Disease Severity 2.8 Treatment 3 Marketed Products 3.1 Overview 3.2 Product Profiles 3.3 Heat Map of Marketed Products 3.4 Conclusion 4 Developmental Pipeline 4.1 Overview 4.2 Mechanisms of Action in the Pipeline 4.3 Clinical Trials 4.4 Promising Pipeline Molecules 4.5 Heat Map of Pipeline Products 4.6 Conclusion 5 Market Forecast to 2019 5.1 Geographical Markets 5.2 Drivers and Barriers 6 Strategic Consolidations 6.1 Major Co-Development Deals 6.2 Major Licensing Deals 7 Appendix Companies Mentioned - Aptalis Pharma - Chiesi Farmaceutici - Forest Laboratories - Genentech - Gilead Sciences - Insmed - Novartis - PTC Therapeutics - Pharmaxis - Vertex Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/5g...c_fibrosis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Nasdaq stocks posting largest volume increases
AP - Thu Feb 13, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading: